13 October 2023
13 October 2023
The treatment is indicated for usage in adult NSCLC patients with a BRAF V600E mutation.
Alvotech intends to resubmit the application for AVT04 shortly, triggering another six-month review cycle.
The investment will ensure that 370 million children in low-income countries will be vaccinated against polio each year.
Care Access has been exonerated of wrongdoing at its clinical sites, but Pfizer and Valneva’s Phase III trial is now one year behind schedule.
The Phase III trial of ALK’s allergy immunotherapy tablet met its primary endpoint for the treatment of tree-pollen-induced allergic rhinoconjunctivitis.
Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.
Immetas Therapeutics and GC Biopharma announced a collaboration for mRNA therapeutic development.
The team at the Institute of Cardiovascular Sciences says the development of these nanobodies will allow them to develop new ways of tracking the development of thrombosis.
Join us on October 17th, as Boris Baňas and Jan Storch discuss the challenges of sourcing certified cannabis for clinical trials and delve into CB21 Pharma's cannabis-derived product portfolio.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
